Yaguang Si

Senior Director Biology at FogPharma

Speaker

With over 17 years of experience in cell biology and oncology drug discovery, Yaguang brings a deep expertise that spans from target validation to Investigational New Drug (IND) applications. As Senior Director of Biology at FogPharma, he was instrumental in co-leading the discovery of FOG-001, a pioneering Helicon™ peptide inhibitor aimed at the beta-catenin/TCFs interaction—a key pathway in cancers with dysregulated Wnt signaling. In this role, Yaguang oversaw all preclinical biology activities of the FOG-001 program, leading to the successful IND submission in 2023. Before his tenure at Fog Pharmaceuticals, Yaguang dedicated over eight years to Agios Pharmaceuticals. There, he played a pivotal role in the oncology target validation team, and also contributed to the discovery biology of mitapivat (PYRUKYND®) and the translational biology for ivosidenib (TIBSOVO®). Yaguang holds a Ph.D. in Biology from Tufts University and a B.S. from Fudan University.